The Mumbai-based pharma and biotech major Wockhardt will launch its Levetiracetam tablets in the United States soon. The company received approval from the United States Food & Drug Administration (US FDA) for marketing the tablets containing 250 mg, 500 mg, 750 mg and 1gm Levetiracetam which is used to treat various kinds of epileptic seizures. Levetiracetam is the generic name for the brand Keppra, marketed in the USA by UCB. According to IMS, the total market for Levetiracetam tablets in the US is $1.07 billion.

"CNS drugs, especially anti-epileptic drugs form a significant portion of Wockhardt's growing product portfolio in the USA," said Wockhardt chairman Habil Khorakiwala. "With nearly sixty products now in the market, we are continuing to strengthen Wockhardt's US business by filing several ANDA's, including technologically challenging products, all indigenously developed by Wockhardt's R&D team," he added.

Wockhardt's Levetiracetam tablets will be launched in the US shortly. In the prescription generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products.

The tablets will be manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The product was developed in-house.